07:00 , Apr 14, 2003 |  BC Week In Review  |  Company News

Biosynexus, Nutrition 21 deal

Nutrition 21 received a milestone from Biosynexus triggered by the start of a clinical trial. Biosynexus acquired worldwide exclusive rights to nisin and lysostaphin compounds from Nutrition 21, formerly AMBI Inc. , to treat drug...
08:00 , Dec 9, 2002 |  BioCentury  |  Finance

Ebb & Flow

The preferred currency for biotech M&A has been stock rather than cash, because most CEOs want to keep the latter to fund R&D. Thus, it's notable that Triangle (VIRS) is the third Warburg Pincus portfolio...
08:00 , Dec 3, 2001 |  BC Week In Review  |  Clinical News

Gencap microparticle DNA delivery technology regulatory update

The Center for Applied Microbiology & Research (Salisbury, U.K.) received U.S. Patent No. 6,309,569 covering methods of encapsulating DNA in microparticles. Zycos, which is the exclusive licensee, said the patent is related to its Gencap...
07:00 , Oct 10, 2001 |  BC Extra  |  Politics & Policy

U.S., U.K. sign bio-terrorism accord

The U.S. and the U.K. on Wednesday signed an agreement to bolster their bio-terrorism defense capabilities. Under the agreement, signed by HHS Secretary Tommy Thompson and UK Minister of Health Alan Milburn, the two countries...
07:00 , Aug 6, 2001 |  BC Week In Review  |  Company News

Genencor, Centre for Applied Microbiology & Research deal

The parties signed an exclusive two-year deal to develop a technology to eliminate prions, believed to be the infectious agent in Bovine Spongiform Encephalopathy (BSE). The deal combines GCOR's protease platform targeting technology, assay development...
08:00 , Mar 5, 2001 |  BC Week In Review  |  Company News

AMBI other research news

AMBI said that in cell culture, its product combining chromium picolinate ( CP ) with alpha lipoic acid (APA) significantly increased glucose uptake by insulin-stimulated muscle cells and that its product combining CP with conjugated...
08:00 , Jan 2, 2001 |  BC Week In Review  |  Company News

AMBI, University of North Carolina deal

AMBI obtained an option to exclusively license the university's U.S. Patents Nos. 5,972,390 and 6,034,125 covering the use of chromium as a nutritional supplement to treat depression and pre-menstrual syndrome. Ambi Inc. (AMBI), Purchase, N.Y....
08:00 , Jan 2, 2001 |  BC Week In Review  |  Clinical News

Lactic acid producing bacteria data

Ganeden said that its lactic acid producing bacteria significantly reduced density and duration of multiple strains of VRE in mice compared with controls. The results will be published in the Journal of Applied Microbiology. Ganeden...
08:00 , Dec 18, 2000 |  BC Week In Review  |  Clinical News

Taste-masking technology regulatory update

AMBI received U.S. Patent No. 6,156,332 covering the composition and use of its masking technology to reduce the unpleasant taste and after-taste of mineral supplements, including potassium, calcium, zinc and magnesium. AMBI Inc. (AMBI), Purchase,...
08:00 , Nov 20, 2000 |  BC Week In Review  |  Company News

AMBI nutraceuticals news

AMBI will restructure and reduce its staff, which the company estimates will save $3.5 million annually. AMBI discontinued its launch of NoYo, a weight loss product, and said it will seek a partner to help...